글로벌 신경성 폭식증 약물 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 폭식증 신경증 약물 시장

신경성 폭식증 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 5.20%의 잠재적 성장률을 기록할 것으로 예상됩니다. 연구 개발에 대한 투자 증가가 시장 성장의 원인입니다.

신경성 폭식증은 단시간에 많은 양의 음식을 먹는 것으로 묘사되는 일종의 섭식 장애입니다. 이 장애는 또한 폭식증으로 알려져 있습니다. 신경성 폭식증은 치아와 잇몸 부식, 심장 문제, 불안 자해, 탈수 및 소화 문제와 같은 여러 가지 생명을 위협하는 심각한 합병증으로 이어집니다.

심리적 장애, 알코올 중독 및 당뇨병의 유병률이 빠르게 증가함에 따라 2021년에서 2028년의 예측 기간 동안 시장 성장이 가속화될 것으로 예상됩니다. 마찬가지로, 알코올 중독 증가와 관련된 라이프스타일의 빠른 변화와 동료 압력의 증가도 신경성 폭식증 약물 시장 성장을 강화할 것으로 예측됩니다. 나아가, 질병의 발생률과 유병률이 증가하고 다양한 기관이 사람들에게 인식을 제고하기 위해 집중하는 것도 시장 성장률을 견인할 것으로 예상됩니다.

또한 효율적인 치료를 위한 기술의 발전 과 의료비 지출의 급속한 증가, 그리고 새로운 보다 나은 치료법을 위한 연구 개발에 대한 정부 지원의 증가는 2021년에서 2028년까지의 예측 기간 동안 이 폭식증 약물 시장 성장에 영향을 미칠 다양한 새로운 기회를 창출할 가능성이 높습니다.

그러나 특히 신경성 폭식증 치료를 위한 약물이 부족하고 치료 옵션에 대한 인식이 부족한 것이 신경성 폭식증 약물 시장 성장을 저해하는 주요 요인으로 작용할 것으로 예상되며, 치료 비용이 높기 때문에 위에 언급한 예측 기간 동안 타겟 시장 성장에 어려움이 있을 수 있습니다.

This bulimia nervosa drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the bulimia nervosa drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Bulimia Nervosa Drug Market Scope and Market Size

Bulimia nervosa drug market is segmented on the basis of disorder type, drug type, route of administration, distribution channel and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of disorder type, the bulimia nervosa drug market can be segmented into purging and non-purging.
• The drug type segment of the bulimia nervosa drug market can be segmented into antidepressants, antipsychotics, selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, benzodiazepines, and others.
• Based on route of administration, the bulimia nervosa drug market can be segmented into oral, intravenous and others.
• On the basis of distribution channel, the bulimia nervosa drug market can be segmented into hospital pharmacies, retail pharmacies and online pharmacies.
• On the basis of end users, the bulimia nervosa drug market can be segmented into hospitals, clinics, homecare, specialty centers and others.

Bulimia Nervosa Drug Market Country Level Analysis

Bulimia nervosa drug market is analyzed and market size information is provided by country by disorder type, drug type, route of administration, distribution channel and end users as referenced above.

The countries covered in the bulimia nervosa drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the bulimia nervosa drug market due to presence of well developed healthcare infrastructure and rise in the prevalence of bulimia nervosa. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rise in the awareness regarding mental disorders and increase in the incidence rate of bulimia nervosa.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Bulimia nervosa drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Bulimia Nervosa Drug Market Share Analysis

Bulimia nervosa drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bulimia nervosa drug market.

The major players covered in the bulimia nervosa drug market report are Allergan, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer, Inc., Johnson & Johnson Services, Inc., Novo Nordisk A/S,  Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma, Novartis AG, Medtronic, Zydus Cadila, AbbVie Inc,  Apotex Inc., Teva Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co., Ltd.,  F. Hoffmann-La Roche Ltd, and Sun Pharmaceutical Industries Ltd., among other domestic and global players. Bulimia nervosa drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-44904